Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytomegalovirus-specific T cells - Kalaris Therapeutics

Next Previous
Drug Profile

Cytomegalovirus-specific T cells - Kalaris Therapeutics

Alternative Names: CMV-specific T cell therapy - Kalaris Therapeutics; CMV-specific T cells - Kalaris Therapeutics; Cytomegalovirus-specific T cell therapy - Kalaris Therapeutics; HLA-matched Viralym-C cells; Human leukocyte antigen (HLA)-matched CMV-specific T lymphocytes - Kalaris Therapeutics; Viralym-C

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViraCyte
  • Developer Kalaris Therapeutics
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 18 Mar 2025 AlloVir has merged with Kalaris Therapeutics to form Kalaris Therapeutics
  • 22 May 2019 ViraCyte is now called AlloVir
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Cytomegalovirus infections(In adolescents, In children, In adults) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top